<DOC>
	<DOCNO>NCT02753426</DOCNO>
	<brief_summary>The goal trial evaluate whether subantimicrobial-dose doxycycline ( 20mgBID ) affect serum urine biomarkers fibrosis patient pre-dialysis chronic kidney disease .</brief_summary>
	<brief_title>Doxycycline : A Novel Treatment Cardiorenal Syndrome</brief_title>
	<detailed_description>This Phase I , placebo-controlled , randomize crossover trial determine effect 4-week treatment subantimicrobial-dose doxycycline serum urine biomarkers fibrosis patient pre-dialysis chronic kidney disease ( eGFR &lt; 30ml/min/1.73m2 ) . Doxycycline matrix metalloproteinase inhibitor approve use anti-fibrotic setting gum skin disease low dos ( 20mgBID ) . At dose , serum level low antimicrobial effect chronic usage think lead tetracycline resistance . Investigators hypothesize doxycycline ameliorate cardiac renal fibrosis thus investigator detect decrease fibrotic marker treatment doxycycline .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>CKD predialysis ( eGFR &lt; 30 ml/min/1.73m2 dialysis ) ; local 415/650/510 area code ; primary language English Spanish eGFR worsen great 5ml/min/1.73 m2 last 6 month ; SBP le 100mmHg great 170 mmHg ; pregnancy ; ejection fraction le 45 % ; NYHA class III IV HF ; myocardial infarction hospitalization HF within 4 month ; liver disease ; moderate severe chronic obstructive pulmonary disease pulmonary fibrosis ; current infection ; chemotherapy ; major surgery within last month ; bilateral dialysis access preclude lab draw ; selfreported use IV drug cocaine within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>